emitbio

Durham firm projects $4B in healthcare savings if blue light tech used to treat COVID-19

Posted by Jason Parker | Jul 20, 2022

A study co-authored by the CFO of Durham-based EmitBio modeled potential cost savings if its technology could be used to treat COVID-19.

COVID-19 treatment at home could come from Durham firm’s blue light tech

Posted by Jason Parker | Feb 9, 2022

EmitBio says a study found the company’s blue light treatment to be 99.99% effective against COVID variants. WRAL TechWire talks with the company’s CEO.

Study: EmitBio’s blue light biotech can eliminate 99.99% of Omicron in lab setting

Posted by Jason Parker | Feb 1, 2022

EmitBio announced the results of an in vitro laboratory study, and says its technology can eliminate 99.99% of the Omicron variant.

EmitBio granted U.S. patent for the use of light to limit, eliminate virus that causes COVID-19

Posted by Jason Parker | Nov 2, 2021

EmitBio has been awarded a patent for its biotechnology therapy to treat respiratory pathogens, like SARS-CoV-2 and its variants, including Delta, and a peer-reviewed manuscript describing the process and application of light therapy was published in Scientific Reports.

Durham firm says its light technology can ‘inactivate’ COVID-19 variants

Posted by WRAL TechWire | Mar 10, 2021

Durham-based EmitBio, which is seeking FDA authorization for use of its light technology to combat COVIDA-19, says its proprietary technology can inactivate variants of the coronavirus that causes COVID-19.